StockData
Guided Therapeutics Inc logo

Guided Therapeutics Inc (GTHP) stock

GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.16−0.03 (-15.79%)

Close on Oct 19, 2026Market cap $15.45MP/E –Yield –

Guided Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Guided Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 75.8%. For fiscal 2025 it was 74.4%, against 28.6% the year before. The highest annual figure on record is 140.2% in fiscal 2020.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202574.4%+45.9
FY2024Dec 31, 202428.6%−8.2
FY2023Dec 31, 202336.7%+559.8
FY2022Dec 31, 2022-523.1%−547.8
FY2021Dec 31, 202124.7%−115.5
FY2020Dec 31, 2020140.2%+234.6
FY2019Dec 31, 2019-94.4%−38.3
FY2018Dec 31, 2018-56.1%+61.1
FY2017Dec 31, 2017-117.2%−181.5
FY2015Dec 31, 201564.3%+268.9
FY2014Dec 31, 2014-204.6%−173.9
FY2013Dec 31, 2013-30.7%−29.4
FY2012Dec 31, 2012-1.3%+0.9
FY2011Dec 31, 2011-2.3%−102.3
FY2010Dec 31, 2010100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 202577.6%+11.0
Q3 FY2025Sep 30, 202558.3%+8.3
Q2 FY2025Jun 30, 202567.5%+42.5
Q4 FY2024Dec 31, 2024-200.0%−259.1
Q1 FY2024Mar 31, 202466.7%−33.3
Q4 FY2023Dec 31, 202350.0%−30.0
Q2 FY2023Jun 30, 202325.0%−55.0
Q1 FY2023Mar 31, 202359.1%−9.2
Q3 FY2022Sep 30, 2022100.0%+221.1
Q2 FY2022Jun 30, 202280.0%−20.0
Q1 FY2022Mar 31, 202280.0%−260.0
Q4 FY2021Dec 31, 202168.3%−16.1
Q3 FY2021Sep 30, 2021-121.1%−196.1
Q2 FY2021Jun 30, 2021100.0%+0.0
Q4 FY2020Dec 31, 2020340.0%+6740.0
Q3 FY2020Sep 30, 202084.4%−10.0
Q4 FY2019Dec 31, 201975.0%+179.8
Q3 FY2019Sep 30, 2019100.0%+0.0
Q2 FY2019Jun 30, 2019-6400.0%−6487.5
Q1 FY2019Mar 31, 201994.4%+69.4
Q4 FY2018Dec 31, 2018-104.8%+108.3
Q3 FY2018Sep 30, 2018100.0%+293.9
Q2 FY2018Jun 30, 201887.5%+81.8
Q1 FY2018Mar 31, 201825.0%+1.2
Q4 FY2017Dec 31, 2017-213.1%−223.6
Q3 FY2017Sep 30, 2017-193.9%–
Q2 FY2017Jun 30, 20175.7%–
Q1 FY2017Mar 31, 201723.8%–
Q3 FY2016Sep 30, 201610.5%–

More Guided Therapeutics figures

See a number that looks wrong?